查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1301033

臨床腫瘤學下一代測序市場規模、份額和趨勢分析報告：按工作流程（NGS 預測序、NGS 數據分析）、按技術、按應用、按最終用途、按地區、細分市場趨勢，2023-2030 年

Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-sequencing, NGS Data Analysis), By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

臨床腫瘤學下一代測序市場增長和趨勢

根據 Grand View Research, Inc. 的最新報告，預計到 2030 年，全球臨床腫瘤學下一代測序市場將達到 11.6 億美元。

從 2023 年到 2030 年，市場預計將以 15.7% 的複合年增長率擴張。 臨床腫瘤學下一代測序（NGS）市場需求量很大。 由於有效的個性化醫療和癌症治療方法的開發以及醫療保健支出的增加引發了 NGS 採用的增加，預計增長率在預測期內將會增加。

不斷上漲的醫療保健成本和有效癌症治療方法的出現預計將在預測期內推動市場增長。 JAMA Network 於 2023 年 2 月發表的一項研究估計，2020 年至 2030 年 30 年間，全球癌症治療費用將高達 25 萬億美元。 研究發現，高收入國家治療費用對癌症總經濟支出的相對貢獻高於低收入國家。 此外，正在開發各種治療技術並將其用於癌症的診斷和治療。 根據 Wiley 2023 年 1 月發表的一項研究，用於開發新診斷技術的技術進步包括圖像重建軟件、診斷成像設備、硬件、生物標誌物和人工智能算法，從而能夠對腫瘤進行可靠的分析和診斷。

此外，在預測期內，NGS 相對於單基因檢測的日益普及也推動了臨床腫瘤學下一代測序市場的增長。 大量研究表明，NGS 比單基因檢測更具成本效益和效率。 例如，JCO Precision Oncology 於 2023 年 3 月發表的一項研究發現，在西班牙參考中心採用 NGS 診斷 NSCLC 患者是比單基因檢測更具成本效益的策略。我的結論是。 此外，國家醫學圖書館於 2023 年 1 月進行的一項研究表明，當前 NGS 的年度成本略低於序貫單基因檢測。 然而，採用 NSG 測試而不是 SSG 測試可以縮短平均交付時間，有利於日本小細胞肺癌患者快速識別基因組改變並儘早開始治療。 預計這些因素將在預測期內推動市場。

臨床腫瘤學下一代測序市場報告亮點

  • 在工作流程領域，由於技術進步和癌症測序項目的增加，NGS 測序將在 2022 年以 56.0% 的銷售份額佔據市場主導地位
  • 按技術劃分，2022 年，靶向測序和重測序在臨床腫瘤 NGS 市場中佔據最大收入份額，達到 72.7%。 這是由於靶向組的臨床實用性增加和癌症腫瘤檢測的高效率。
  • 從應用來看，2022年篩查領域佔比最高，達到80.1%。 該細分市場的主導地位是全球癌症患病率的又一次上升。
  • 按最終用途劃分，到 2022 年，實驗室領域將佔據臨床腫瘤 NGS 市場的最大份額，達到 64.1%。 這是由於研究和開發活動的增加。
  • 2022 年，北美市場份額最大，達到 48.68%。 該地區的主導地位部分歸因於市場上知名國際參與者的存在，以及公共和私人機構對該地區生命科學研究和解決方案開發的投資不斷增加。

內容

第1章調查方法及範圍

  • 信息獲取
  • 信息或數據分析
  • 市場範圍和細分定義
  • 市場模式
    • 按公司市場份額進行市場調查
    • 區域分析

第 2 章執行摘要

  • 市場概況
  • 片段快照
  • 競爭格局快照

第3章市場變量、趨勢和範圍

  • 市場體系展望
    • 母公司市場前景
    • 相關/補充市場前景
  • 市場動態
    • 市場驅動因素分析
    • 市場製約因素分析
  • 行業分析工具
    • SWOT 分析：按因素（政治/法律、經濟/技術）
    • 波特五力分析
    • 2022 年採用率和增長前景圖
  • COVID-19 的影響分析

第 4 章臨床腫瘤學下一代測序市場分類：技術評估和趨勢分析

  • 臨床腫瘤學NGS市場：技術波動分析
  • 按技術
  • 全基因組測序
    • 臨床腫瘤學市場的全基因組測序，2018-2030 年（百萬美元）
  • 全外顯子組測序
    • 2018-2030 年臨床腫瘤學市場的全外顯子組測序（百萬美元）
  • 靶向測序和重測序
    • 2018-2030 年臨床腫瘤市場的靶向測序和重測序（百萬美元）

第 5 章臨床腫瘤學下一代測序市場分類：工作流程估計和趨勢分析

  • 臨床腫瘤學 NGS 市場：工作流程變化分析
  • 按工作流程
  • NGS 預測序
    • 2018-2030 年臨床腫瘤學市場的 NGS 預測序（百萬美元）
  • NGS 序列
    • 2018-2030 年臨床腫瘤學市場的 NGS 測序（百萬美元）
  • NGS數據分析
    • 2018-2030 年臨床腫瘤市場 NGS 數據分析（百萬美元）

第 6 章臨床腫瘤學下一代測序市場分類：應用估算和趨勢分析

  • 臨床腫瘤學 NGS 市場：應用變化分析
  • 按最終用途
  • 篩選
    • 2018-2030 年臨床腫瘤學 NGS 市場篩查（百萬美元）
    • 散發性癌症
    • 遺傳性癌症
  • 伴隨診斷
    • 伴隨診斷、臨床腫瘤學 NGS 市場，2018-2030 年（百萬美元）
  • 其他診斷
    • 其他診斷臨床腫瘤學 NGS 市場，2018-2030 年（百萬美元）

第 7 章臨床腫瘤學下一代測序市場分類：最終用途估計和趨勢分析

  • 臨床腫瘤學 NGS 市場：最終用途變異分析
  • 按最終用途
  • 醫院
    • 2018-2030 年醫院臨床腫瘤 NGS 市場（百萬美元）
  • 診所
    • 臨床腫瘤學 NGS 市場，2018-2030 年（百萬美元）
  • 實驗室
    • 實驗室臨床腫瘤學 NGS 市場，2018-2030 年（百萬美元）

第8章臨床腫瘤學下一代測序市場區域業務分析

  • 2022 年和 2030 年臨床腫瘤學下一代測序市場份額（按地區）
  • 北美
    • 北美臨床腫瘤學下一代測序市場，2018-2030 年（百萬美元）
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030 年歐洲臨床腫瘤學下一代測序市場（百萬美元）
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030 年亞太臨床腫瘤學下一代測序市場（百萬美元）
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 泰國
    • 韓國
  • 拉丁美洲
    • 拉丁美洲臨床腫瘤學下一代測序市場，2018-2030 年（百萬美元）
    • 巴西
    • 墨西哥
    • 阿根廷
  • MEA
    • MEA 臨床腫瘤學下一代測序市場，2018-2030 年（百萬美元）
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第 9 章競爭格局

  • 公司分類
  • 戰略規劃
  • 公司簡介/列表
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • Agilent Technologies, Inc.
    • Myriad Genetics, Inc.
    • Beijing Genomics Institute（BGI）
    • QIAGEN
    • Perkin Elmer, Inc.
    • PacBio
    • Partek Incorporated
    • Foundation Medicine Inc.
    • Oxford Nanopore Technologies
    • Paradigm Diagnostics, Inc.
    • Caris Life Sciences
    • Eurofins Scientific
    • PerkinElmer, Inc.
Product Code: GVR-3-68038-791-9

Clinical Oncology Next Generation Sequencing Market Growth & Trends

The global clinical oncology next generation sequencing market size is expected to reach USD 1.16 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.7% from 2023 to 2030. The clinical oncology next generation sequencing (NGS) market is in high demand. It is projected to expand at an increasing rate throughout the forecast period owing to the rising healthcare expenditure triggering the development of effective personalized medicine & therapeutic procedures for cancer and increasing adoption of NGS.

The increasing healthcare expenses and the launch of effective cancer treatments are expected to fuel market growth over the forecast period. A study published by the JAMA network in February 2023 estimated that the cost of cancer treatment can reach up to USD 25 trillion globally over the 30 years from 2020-2030. The comparative contribution of treatment expenses to the total economic expense of cancers was found to be more significant in high-income nations than in low-income nations. Moreover, various treatment techniques are being developed and utilized to diagnose and treat cancer. According to the study published by Wiley in January 2023, technological advances that are being used to develop new diagnostic techniques include image reconstruction software, imaging devices, hardware, biomarkers, and artificial intelligence algorithms, thereby delivering a reliable analysis and diagnosis of the tumor.

Furthermore, the growth of the clinical oncology next-generation sequencing market during the forecast period is propelled by the rise in the adoption of NGS over single gene testing. Many studies demonstrated that NGS is cost-effective and efficient over single gene testing. For instance, a study published by JCO Precision Oncology in March 2023 concluded that the adoption of NGS in Spanish reference centers to diagnose patients with NSCLC could be a cost-effective strategy over single gene testing. In addition, the study given by the National Library of Medicine in January 2023, suggests that the current NGS over sequential single-gene testing can slightly reduce annual costs. However, embracing NSG over SSG testing can decrease the average turnaround time, facilitating quicker identification of genomic alterations and early initiating therapy for small cell lung cancer patients in Japan. These factors are expected to drive the market over the forecast period.

Clinical Oncology Next Generation Sequencing Market Report Highlights

  • In the workflow segment, NGS sequencing dominated the market with a revenue share of 56.0% in 2022, owing to technological advancements and the rising number of cancer sequencing projects
  • By technology, the targeted sequencing and resequencing accounted for the largest revenue share of 72.7% in the clinical oncology NGS market in 2022. This can be attributed to the growing clinical utility of targeted panels and their efficiency in detecting cancer tumors
  • By application, the screening segment held the highest share of 80.1% in 2022. The segment's dominance is due to the increasing prevalence of cancer worldwide
  • By end-use, the laboratories segment accounted for the largest share of 64.1% in the clinical oncology NGS market in 2022. This can be attributed to the rising number of research and development activities
  • North America held the largest market share of 48.68% in 2022. The dominance of the region is due to the presence of prominent international players in the market and rising investments from public and private organizations in life science research & solutions developments in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Decrease in costs for genetic sequencing
      • 3.2.1.2. Advancements in the field of personalized medicine
      • 3.2.1.3. Rise in competition amongst prominent market entities
      • 3.2.1.4. Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
      • 3.2.1.5. Rise in prevalence of cancer
      • 3.2.1.6. Growing adoption of NGS over single gene testing
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of computational efficiency for data management
      • 3.2.2.2. Non-value based NGS reimbursement policy
  • 3.3. Industry Analysis Tools
    • 3.3.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.3.2. Porter's Five Forces Analysis
    • 3.3.3. Penetration and Growth Prospect Mapping, 2022
  • 3.4. COVID-19 Impact Analysis

Chapter 4. Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis

  • 4.1. Clinical Oncology NGS Market: Technology Movement Analysis
  • 4.2. Clinical Oncology NGS Market Estimates & Forecast, By Technology (USD Million)
  • 4.3. Whole Genome Sequencing
    • 4.3.1. Whole Genome Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 4.4. Whole Exome Sequencing
    • 4.4.1. Whole Exome Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted Sequencing & Resequencing
    • 4.5.1. Targeted Sequencing & Resequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)

Chapter 5. Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis

  • 5.1. Clinical Oncology NGS Market: Workflow Movement Analysis
  • 5.2. Clinical Oncology NGS Market Estimates & Forecast, By Workflow (USD Million)
  • 5.3. NGS Pre-Sequencing
    • 5.3.1. NGS Pre-Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 5.4. NGS Sequencing
    • 5.4.1. NGS Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 5.5. NGS Data Analysis
    • 5.5.1. NGS Data Analysis For Clinical Oncology Market, 2018 - 2030 (USD Million)

Chapter 6. Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis

  • 6.1. Clinical Oncology NGS Market: Application Movement Analysis
  • 6.2. Clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  • 6.3. Screening
    • 6.3.1. Screening Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
    • 6.3.2. Sporadic Cancer
      • 6.3.2.1. Sporadic cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
    • 6.3.3. Inherited cancer
      • 6.3.3.1. Inherited cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • 6.4. Companion Diagnostics
    • 6.4.1. Companion diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • 6.5. Other Diagnostics
    • 6.5.1. Other diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)

Chapter 7. Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis

  • 7.1. Clinical Oncology NGS Market: End Use Movement Analysis
  • 7.2. Clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 7.4. Clinics
    • 7.4.1. Clinics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • 7.5. Laboratories
    • 7.5.1. Laboratories clinical oncology NGS market, 2018 - 2030 (USD Million)

Chapter 8. Clinical Oncology Next Generation Sequencing Market Regional Business Analysis

  • 8.1. Clinical Oncology Next Generation Sequencing Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. North America Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Competitive Scenario
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. U.S. Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Canada Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. UK Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Germany Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. France Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Italy Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Spain Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Denmark Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Sweden Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Norway Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Japan Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. China Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. India Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Australia Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Thailand Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. South Korea Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Brazil Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Mexico Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Argentina Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. South Africa Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Saudi Arabia Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. UAE Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Kuwait Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Profiles/Listing
    • 9.3.1. Illumina, Inc.
      • 9.3.1.1. Overview
      • 9.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Thermo Fisher Scientific Inc.
      • 9.3.2.1. Overview
      • 9.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. F. Hoffmann-La Roche Ltd
      • 9.3.3.1. Overview
      • 9.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Agilent Technologies, Inc.
      • 9.3.4.1. Overview
      • 9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Myriad Genetics, Inc.
      • 9.3.5.1. Overview
      • 9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Beijing Genomics Institute (BGI)
      • 9.3.6.1. Overview
      • 9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. QIAGEN
      • 9.3.7.1. Overview
      • 9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Perkin Elmer, Inc.
      • 9.3.8.1. Overview
      • 9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. PacBio
      • 9.3.9.1. Overview
      • 9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Partek Incorporated
      • 9.3.10.1. Overview
      • 9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Foundation Medicine Inc.
      • 9.3.11.1. Overview
      • 9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.11.3. Product Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. Oxford Nanopore Technologies
      • 9.3.12.1. Overview
      • 9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.12.3. Product Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. Paradigm Diagnostics, Inc.
      • 9.3.13.1. Overview
      • 9.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.13.3. Product Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Caris Life Sciences
      • 9.3.14.1. Overview
      • 9.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.14.3. Product Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. Eurofins Scientific
      • 9.3.15.1. Overview
      • 9.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.15.3. Product Benchmarking
      • 9.3.15.4. Strategic Initiatives
    • 9.3.16. PerkinElmer, Inc.
      • 9.3.16.1. Overview
      • 9.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.16.3. Product Benchmarking
      • 9.3.16.4. Strategic Initiatives

List of Tables

  • Table 1 Cancer Incidence and Mortality, By Region, 2018
  • Table 2 Genes associated with breast and ovarian cancer that can be sequenced by NGS panel
  • Table 3 FDA-Approved NGS Tumor-Profiling Tests for Companion Diagnostics
  • Table 4 Gene-panels used in clinics for Hereditary Breast/Ovarian Cancer (HBOC)
  • Table 5 North America clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 6 North America clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 7 North America clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 8 North America clinical oncology NGS screening market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 9 North America clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 11 U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 12 U.S. clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 13 U.S. clinical oncology NGS screening market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 14 U.S. clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 15 Canada clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 16 Canada clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 17 Canada clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 18 Canada clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 20 Europe clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 21 Europe clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 23 Germany clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 24 Germany clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 25 Germany clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 26 Germany clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 27 UK clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 28 UK clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 29 UK clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 30 UK clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 31 France clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 32 France clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 33 France clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 34 France clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 35 Italy clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 36 Italy clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 37 Italy clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 38 Italy clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 39 Spain clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 40 Spain clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 41 Spain clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 42 Spain clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million) 
  • Table 43 Denmark clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 44 Denmark clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 45 Denmark clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 46 Denmark clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million) 
  • Table 47 Sweden clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 48 Sweden clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 49 Sweden clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 50 Sweden clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 51 Norway clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 52 Norway clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 53 Norway clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 54 Norway clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 59 Japan clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 60 Japan clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 61 Japan clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 62 Japan clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 63 China clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 64 China clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 65 China clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 66 China clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 67 India clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 68 India clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 69 India clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 70 India clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 71 South Korea clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 72 South Korea clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 73 South Korea clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 74 South Korea clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 75 Australia clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 76 Australia clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 77 Australia clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 78 Australia clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 79 Thailand clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 80 Thailand clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 81 Thailand clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 82 Thailand clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 83 Latin America clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 84 Latin America clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 85 Latin America clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 86 Latin America clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 87 Brazil clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 88 Brazil clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 89 Brazil clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 90 Brazil clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 91 Mexico clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 92 Mexico clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 93 Mexico clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 94 Mexico clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 95 Argentina clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 96 Argentina clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 97 Argentina clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 98 Argentina clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 99 Middle East & Africa clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 100 Middle East & Africa clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 101 Middle East & Africa clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 102 Middle East & Africa clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 103 South Africa clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 104 South Africa clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 105 South Africa clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 106 South Africa clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 112 UAE clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 113 UAE clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 114 UAE clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 116 Kuwait clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 117 Kuwait clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 118 Kuwait clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market snapshot
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market trends & outlook
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Penetration & growth prospect mapping for application, 2022
  • Fig. 11 Penetration & growth prospect mapping for prominent industry players, 2022
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Cost per raw mega base (Mb) of DNA sequence (USD)
  • Fig. 14 Cost per genome
  • Fig. 15 Expected rise in expenditure for cancer treatment (USD Billion)
  • Fig. 16 Number of new cancer cases in the World, 2022
  • Fig. 17 Market restraint relevance analysis (Current & future impact)
  • Fig. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
  • Fig. 19 Porter's Five Forces Analysis
  • Fig. 20 Strategy framework
  • Fig. 21 Participant categorization
  • Fig. 22 Clinical oncology NGS market: Technology outlook key takeaways
  • Fig. 23 Clinical oncology NGS market: Technology movement analysis
  • Fig. 24 Whole genome sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 25 Whole exome sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 26 Targeted sequencing and resequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 27 Clinical oncology NGS market: Workflow outlook key takeaways
  • Fig. 28 Clinical oncology NGS market: Workflow movement analysis
  • Fig. 29 NGS Pre-sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 30 NGS Sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 31 NGS Data analysis for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 32 Clinical oncology NGS market: Application outlook key takeaways
  • Fig. 33 Clinical oncology NGS market: Application movement analysis
  • Fig. 34 Screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 35 Sporadic cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 36 Lifetime cancer risks for common cancers
  • Fig. 37 Inherited cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 38 Companion diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 39 Other diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 40 Clinical oncology NGS market: End use outlook key takeaways
  • Fig. 41 Clinical oncology NGS market: End use movement analysis
  • Fig. 42 Hospitals clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 43 Clinics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 44 Laboratories clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 45 Regional market place: Key takeaway
  • Fig. 46 Clinical oncology NGS market: Regional outlook, 2018 & 2025
  • Fig. 47 North America clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 49 Canada clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 50 Europe clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 51 Germany clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 52 UK clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 53 France clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 54 Italy clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 55 Spain clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 58 Norway clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 60 Japan clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 61 China clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 63 India clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 68 Mexico clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 70 Middle East & Africa clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 74 Kuwait clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 75 Key companies profiled